New smart drug TQB6411 targets two cancer proteins in early human trial
NCT ID NCT07043751
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 1 trial tests TQB6411, an antibody-drug conjugate designed to bind to EGFR and c-Met proteins on tumor cells, blocking their growth signals and releasing a toxin to kill the cells. The study will enroll 216 adults with advanced malignant tumors to find the safest dose and see if the drug shrinks tumors. It is an early-stage study focused on safety and dosing, not yet a proven treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TQB6411 injection (an antibody-drug conjugate that targets EGFR and c-Met proteins on tumor cells to block growth signals and deliver a toxin to kill cancer cells)
What this could lead to
If this early trial shows safety and hints of tumor shrinkage, it could lead to a new treatment option for advanced cancers that have not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 216 participants, so the drug may prove too toxic or ineffective. It is not yet known if TQB6411 will work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anyang Tumor Hospital
NOT_YET_RECRUITINGAnyang, Henan, 455100, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Beijing Friendship Hospital, Capital Medical University
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100050, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dongguan People's Hospital
NOT_YET_RECRUITINGDongguan, Guangdong, 523059, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fudan University Shanghai Cancer Center
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Guangdong Provincial People's Hospital
NOT_YET_RECRUITINGGuangzhou, Guangdong, 519041, China
Contact Email: •••••@•••••
-
Jiangsu Province Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jining First People's Hospital
NOT_YET_RECRUITINGJining, Shandong, 272002, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mianyang Central Hospital
NOT_YET_RECRUITINGMianyang, Sichuan, 621000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Jiaotong University School of Medicine, Renji Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Pulmonary Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sichuan Cancer Hospital
NOT_YET_RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, 450052, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Hospital of China Medical University
NOT_YET_RECRUITINGShenyang, Liaoning, 110000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Henan Cancer Hospital
NOT_YET_RECRUITINGZhengzhou, Henan, 450008, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Medical University Cancer Institute & Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, 300060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
West China Hospital, Sichuan University
NOT_YET_RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhongnan Hospital Of Wuhan University
NOT_YET_RECRUITINGWuhan, Hubei, 430071, China
Contact Phone: •••-•••-••••
-
ZhuJiang Hospital of Southern Medical University
NOT_YET_RECRUITINGGuangdong, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
the Second Xiangya Hospital of Central South University
NOT_YET_RECRUITINGChangsha, Hunan, 410011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••